- Live market news
- Stocks
- OCGN
Ocugen, Inc.
OCGNStockUnited States
Latest news on OCGNranked by Oyticker for market impact
- 15Impact
Ocugen to Present Gene Therapy Platform at Scientific Conferences
Ocugen announced participation in upcoming scientific conferences to present its modifier gene therapy platform for blindness diseases. Conference presentations are routine disclosure events with limited direct market impact absent new clinical or commercial data.
OCGNBiotechnologyHealthcare - 62Impact
Ocugen Receives Provisional Approval for OCU400 in Bahamas Under Longevity Act
Ocugen's OCU400 gene therapy for retinitis pigmentosa has received provisional approval and priority designation from The Bahamas' LARTA regulatory board, with first patient treatment targeted within 90 days of full approval via expanded access program.
OCGNBiotechnologyGene TherapyHealthcare
What OCGN filed
- 10 Nov 2026
Investor communication
- 4 Nov 2026
- 4 Nov 2026
- 15 Oct 2026
- 14 Oct 2026
Investor communication · Other event
- 5 Oct 2026
- 22 Sept 2026
- 8 Sept 2026
Other event
- 6 Aug 2026
- 6 Aug 2026
- 30 Jul 2026
- 13 Jul 2026
- 11 Jun 2026
Other event
- 3 Jun 2026
- 14 May 2026
From SEC EDGAR, the public record of what US-listed companies file. Each document opens on sec.gov.
Oyticker provides market information and analysis for educational purposes. It is not investment advice: you remain responsible for your own decisions.